X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration will evaluate Nektar's NKTR-255, a novel IL-15 receptor agonist, in combination with CBMG's C-TIL051, a tumor-infiltrating lymphocyte (TIL) therapy, in advanced non-small cell lung cancer (NSCLC) patients that are relapsed or refractory to anti-PD-1 therapy.
Lead Product(s): NKTR-255,C-TIL051
Therapeutic Area: Oncology Product Name: NKTR-255
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Nektar Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 27, 2023
Details:
Through the collaboration, Janssen enhances its portfolio in B-cell malignancies and strengthens its legacy in hematology, by including C-CAR039 (prizloncabtagene autoleucel), a novel bispecific CAR-T therapy targeting both CD19 and CD20 antigens for the treatment R/R DLBCL.
Lead Product(s): Prizloncabtagene Autoleucel
Therapeutic Area: Oncology Product Name: C-CAR039
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: $245.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 02, 2023
Details:
FDA has granted C-CAR039 both RMAT and FTD, based on the result that showed overall response rate of 92.6%, and a complete response rate of 85.2% in relapsed or refractory diffuse large B cell lymphoma.
Lead Product(s): C-CAR039
Therapeutic Area: Oncology Product Name: EXP039
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2022
Details:
C-CAR039, an autologous bi-specific CAR-T cell therapy targeting both CD19/CD20 for treatment in adult patients with relapsed/refractory B-cell non-Hodgkin lymphomas. Clinical study results from an ongoing multicenter trial conducted in China have shown 92.6% response rate.
Lead Product(s): C-CAR039
Therapeutic Area: Oncology Product Name: EXP039
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2021
Details:
The financing will largely be used to accelerate the clinical development of the Company's immune-oncology platform specifically, C-CAR039, an anti-CD19/CD20 bispecific CAR-T therapy for the treatment of patients with relapsed or refractory non-Hodgkin lymphoma.
Lead Product(s): C-CAR039
Therapeutic Area: Oncology Product Name: EXP039
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AstraZeneca-CICC Fund
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 30, 2021
Details:
C-CAR066, a novel second generation chimeric antigen receptor T (CAR-T) therapy targeting CD20 antigen in relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) that has failed to an anti-CD19 CAR-T therapy.
Lead Product(s): C-CAR066
Therapeutic Area: Oncology Product Name: C-CAR066
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2021
Details:
C-TCR055 is CBMG's proprietary clinical lead of TCR-T which specifically recognizes the HLA-A*02:01 restricted AFP158-166 peptide that is highly expressed in hepatocellular carcinoma (HCC) and other solid tumors.
Lead Product(s): AFP TCR T Cells
Therapeutic Area: Oncology Product Name: C-TCR055
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
Cellular has started to collaborate with Shanghai Ruijin Hospital on a pilot clinical study on inhalation of mesenchymal stem cell exosomes treating severe Novel Coronavirus Pneumonia.
Lead Product(s): Mesenchymal stem cell exosomes
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
